medigraphic.com
ISSN 1561-2961 (Print)

2019, Number 2

<< Back Next >>

Rev Cuba Enf 2019; 35 (2)

Good clinical practices in Heberprot-P® usage in patients with diabetic foot ulcer

Jay CB, Sánchez HZ, Kindelán MLM, Cámbara TY

Language: Spanish
References: 20
Page: 1-14
PDF size: 181.04 Kb.


ABSTRACT

Introduction: Diabetes mellitus is a common chronic disease. 50% of nontraumatic amputations of the lower limb occur in diabetic patients and 85% of these amputations are preceded by a diabetic foot injury.
Objective: To describe the outcomes of Heberprot-P® usage in diabetic foot ulcers.
Methods: A descriptive, cross-sectional study was carried out at Ramón López Peña Polyclinic in Santiago de Cuba, from January to December 2015. The study population consisted of 19 patients diagnosed with diabetic foot ulcer and who were administered intralesional Heberprot-P®. The variables studied were sex, age, type of diabetes, classification of the lesions according to Wargner, treatment dose, affected member and location, adverse reactions and treatment outcome.
Results: Patients between 50 and 59 years of age (36.84%) and female participants (52.60%) predominated. The lesions treated were Wagner II, with prevalence of type 2 diabetes; depending on the location, the hallux accounted for 36.83%. 31.57% of patients were administered up to five doses of treatment. The lower left limb was the most affected (68.39%) and 89.48% of the patients had total closure.
Conclusions: For the context of the usual clinical practice and for the evolution of patients treated with Heberprot-P®, this product continues to be a safe and effective medication in the treatment of diabetic foot ulcers. The use of this medicine should not be seen as an isolated therapy, but as part of a prevention strategy designed to reduce the effect of modifiable risk factors in diabetic patients.


REFERENCES

  1. Quirantes Hernández A, López Granja L, Curbelo Serrano V, Montano Luna JA, Machado Leyva P, Quirantes Moreno A. La calidad de la vida del paciente diabético. Rev Cubana Med Gen Integr. 2000 [acceso: 08/07/2016];16(1):50-6. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252000000100009&lng=es

  2. Wilson DJ. Amputation and the diabetic foot: learning from a case study. British Journal of Community Nursing. 2005;10(12 Suppl):18-24.

  3. Brem H, Sheehan P, Rosenberg HJ, Schneider JS, Boulton AJ. Evidence-based protocol for diabetic foot ulcers. Plast Reconstr Surg. 2006;117(Suppl 7):193-209.

  4. Vuolo J. Why people with diabetes suffer foot ulceration? Nurs Times. 2007;103(15):44-6.

  5. Álvarez Duarte H, Hernández Carretero J, Arpajón Peña Y, Gálvez Valcárcel JR, Reynaldo Concepción D, Jay Carbonell VG. Beneficios de la intervención con ozonoterapia en pacientes con pie diabético neuroinfeccioso. Rev Cubana Angiol Cir Vasc. 2014 [acceso: 08/07/2016];15(1). Disponible en: Disponible en: http://bvs.sld.cu/revistas/ang/vol15_1_14/ang03114.htm

  6. Jeffcoate WJ, Lipsky BA, Berendt AR, Cavanagh PR, Bus SA, Peters EJ, et al. Un-resolved issues in the management of ulcers of the foot in diabetes. Diabet Med. 2008;25(12):1380-9.

  7. Fernández Montequín JI, Valenzuela Silva CM, Díaz OG, Savigne W, Sancho Soutelo N, Rivero-Fernández F, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: Multicenter, randomised, placebo-controlled, double-blind study. IntWound J. 2009;6(6):432-43.

  8. Fernández Montequin J, Santiesteban L. Experiencias en el uso del Heberprot-P en Venezuela. Reportes de casos del hospital Carlos Arvelo, Caracas. Infiltración del factor de crecimiento epidérmico. Un tratamiento eficaz para la úlcera del pie diabético. La Habana: Editorial Elfos Scientiae; 2009.

  9. Ministerio de Salud Pública. Anuario estadístico 2015 [acceso: 12/07/2016]. Disponible en: http://files.sld.cu/dne/files/2016/04/Anuario_2015_electronico-1.pdf

  10. Vejerano P, Rivero F, Travieso R, González L. Morbilidad y mortalidad por pie diabético en nuestro servicio. Rev Cubana Endocrinol. 1990;1(2):142-7

  11. Hernández Rivero MJ, Llanes Barrios JA, Acosta Lapera DS. Heberprot-P, una terapia eficaz en la prevención de la amputación en el pie diabético. Rev Cubana Ang Cirug Vasc. 2009 [acceso: 20/11/2012];10(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol10_1_09/ang02109.htm

  12. García Herrera AL, Fernández Montequín J, editores. Generalidades del pie diabético. En: editores. El pie diabético. Madrid: Elsevier; 2004. p. 1-27.

  13. García Herrera AL. Comportamiento de la diabetes mellitus y pronóstico de la lesión neuropática e infecciosa del diabético. Rev Méd Electrón. 2007 [acceso: 07/02/2012];29(5). Disponible en: http://www.revmatanzas.sld.cu/revista %20medica/ano2007/vol5 %202007 /tema02.htm

  14. Fernández-Montequín JI, Betancourt BY, Leyva-González G, López Mola E, Galán-Naranjo K, Ramírez-Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):67-72.

  15. Franco Pérez N, Valdés Pérez C, Llanes Barrios JA, Reynaldo Concepción D, Pérez Leonard D. Las amputaciones de dedos abiertas y cerradas: su evolución en el pie diabético. Rev Cubana Ang Cir Vasc. 2010 [acceso: 08/09/2015];11(1):12-23. Disponible en: http://bvs.sld.cu/revistas/ang/vol11_01_10/ang10110.pdf

  16. Sun JH, Tsai JS. Risk factors for lower extremity amputation in diabetic foot disease categorized by Wagner classification. Diabetes Res ClinPract. 2012;95(3):358-63.

  17. Margolis DJ, Malay DS, Hoffstad OJ. Prevalence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006 to 2008: Data Points#1. Data Points Publication Series Rockville (MD): Agency for Healthcare Research and Quality (US). 2011 [acceso: 12/03/2016]. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK63602

  18. Pinzur MS, Slovenkai MP, Trepman E, Shields NN. Guidelines for diabetic foot care: Recommendations endorsed by the Diabetes Committee of the American Orthopaedic Foot and Ankle Society. FootAnkleInt. 2005;26(1):113-9.

  19. Rivero Fernández F. Experiencias del Programa de atención integral a pacientes con pie diabético en el estado Zulia, Venezuela. Biotecnol Apl. 2010 [acceso: 12/03/2016];27(2). Disponible en: http://scielo.sld.cu/scielo.php?pid=S1027-28522010000200004&script=sci_arttext

  20. Gallardo PV, Zangronis L, Hernández L. Perfil epidemiológico del pie diabético. Angiología. 2004 [acceso: 07/08/2006];5(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol5_1_04/ang16104.htm




2020     |     www.medigraphic.com